Robert Lee, MD
Radiation Oncology · Salt Lake City, UTNPI 1548219991
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 35 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations.
Across 35 payments — averaging $21.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$127
- Varian Medical Systems, Inc.$94
- Boston Scientific$82
- AstraZeneca$64
- Merck$48
- Novo Nordisk$45
- plus $293 from 12 others
Across 6 payments — averaging $1775.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$11K
What the payments were for
- Food & beverage$752100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 8 | $127 |
| Varian Medical Systems, Inc. | 1 | $94 |
| Boston Scientific | 3 | $82 |
| AstraZeneca | 3 | $64 |
| Merck | 2 | $48 |
| Novo Nordisk | 2 | $45 |
| Pharmacosmos Therapeutics Inc. | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| Deciphera Pharmaceuticals Inc. | 2 | $38 |
| EMD Serono, Inc. | 2 | $28 |
| Tersera Therapeutics LLC | 1 | $22 |
| Pfizer | 1 | $20 |
| Astellas Pharma US Inc | 1 | $20 |
| Incyte Corporation | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Bayer | 1 | $17 |
| Seagen Inc. | 1 | $17 |
| AbbVie | 1 | $15 |
How this compares
$752 in reported general payments places this provider in the 55th percentile of 49 radiation oncology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 136 | $2,164 |
| Oxybutynin Chloride ErOxybutynin Chloride | 45 | $490 |
| Ciprofloxacin Hcl | 43 | $149 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 11 | $103 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Salt Lake City
- Jonathan TwardSalt Lake City$114K
- David GaffneySalt Lake City$22K
- Douglas HoltSalt Lake City$3K
- Kristine KokenySalt Lake City$3K
- Matthew PoppeSalt Lake City$2K
- John HayesSalt Lake City$1K
- Shane LloydSalt Lake City$1K
- Ying HitchcockSalt Lake City$1K
- Thomas SkidmoreSalt Lake City$831
- Amy StrowbridgeSalt Lake City$741
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.